The invention relates genes that are deregulated in Parkinson's disease t issues and the corresponding proteins are identified. These genes and the co rresponding proteins are suitable targets for the treatment of Parkinson's d isease. Also, the invention relates to compounds and their uses, particularl y in the pharmaceutical industry. The invention more specifically relates to new uses of compounds that activate the B2 bradykinin receptor, for treatin g neurodegeneration involving oxidative stress and, more particularly, Parki nson's disease. The invention also relates to corresponding methods of treat ment, and can be used in human subjects for preventive or curative treatment , either alone or in combination with other active agents or treatments.</SD OAB>
IDENTIFICATION AND USE OF GPRC VARIANTS IN THE TREATMENT ANDDIAGNOSIS OF PARKINSON'S DISEASE